Evidence for the Effectiveness of Soy in Aging and Improving Quality of Life by Arjmandi, Bahram Herman & Foley, Elizabeth Marie
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Evidence for the Effectiveness 
of Soy in Aging and Improving 
Quality of Life
Bahram Herman Arjmandi and Elizabeth Marie Foley
Abstract
Soy is a highly nutritious yet widely underutilized food. Because of the con-
troversy surrounding soy, individuals with chronic disease states that may benefit 
from soy or soy isoflavone consumption may avoid this food. The relationship of 
soy to estrogen, breast cancer, osteoarthritis, and other chronic disease states is 
discussed. Osteoarthritis is a specific focus, as the immobility brought about by this 
disease state may lead to other chronic diseases that are also positively affected by 
soy consumption, and because there is no clear etiology or cure for this debilitating 
disease. Conclusions and future directions for soy research as it relates to healthy 
aging are also discussed.
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1. Introduction
Globally, life expectancy has increased by nearly 20 years in both sexes since the 
1950s [1]. In the United States (US) in 2015, life expectancy at birth was calculated 
to be almost 79 years old for both males and females [2]. While these numbers are 
encouraging, the quality of life of these individuals has not increased along with 
this increased life expectancy [3]. There are many factors that can influence qual-
ity of life but chronic diseases such as osteoporosis, osteoarthritis, heart disease, 
sarcopenia, type 2 diabetes (T2D), and dementia all play a role in the quality of life 
(QOL) of aging individuals.
Many chronic diseases are highly preventable and are generally treatable through 
diet and exercise. Indeed, poor diet and inadequate physical activity are two of the 
three most common risk factors for several chronic diseases, and addressing these 
factors in addition to the third risk factor, smoking, reduces the risk of cardiovas-
cular disease (CVD), stroke, and T2D by 80% [4]. A 2013 study which analyzed the 
effect of physical inactivity on chronic disease estimated that, worldwide, physical 
inactivity is linked to 6–10% of chronic diseases that included CVD, T2D, breast can-
cer, and colon cancer, and that inactivity is associated 9% of premature deaths [5].
Knee osteoarthritis (OA) has been ranked as one of the top contributors to global 
disabilities in the world [6]. Osteoarthritis is a degenerative disorder of synovial 
joints characterized by focal loss of articular cartilage with reactive changes in 
subchondral and marginal bone, synovium and para-articular structures [7]. These 
degenerative changes lead to the primary complaints of pain with movement, 
stiffness, instability, and loss of function, particularly in those with knee OA [8]. 
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The World Health Organization (WHO) estimates that about 10% of individuals 
60 years or older have OA, an estimate that will only increase as the world’s popula-
tion continues to age due to longer life expectancies [9]. The conclusive etiology 
of this disease is unknown, but injury to the joint, age, gender, and obesity are all 
known factors to contribute to the development of OA [10]. There is also mount-
ing evidence that leptin may play a key role in the pathophysiology of OA. Leptin 
concentration in the serum is positively correlated with Body Mass Index (BMI)  
[11, 12]. This finding is significant as it helps to explain why obesity is a risk factor 
for OA, even in non-weight bearing joints such as hands.
Because individuals with OA are in constant pain, they are likely to stop exercis-
ing or to engage in any physical activity, thus increasing their risk of morbidity. It 
may also lead to other chronic diseases, both as a result of the lack of exercise, and 
the possibility of weight gain and the risks associated with excess weight. In fact, 
T2D has been shown to be a risk factor for knee OA progression [13], indicating that 
these disease states feed off of each other. While exercise is incredibly important for 
health, nutrition may be a much more helpful and significant treatment for indi-
viduals with chronic diseases, specifically OA, because the source of many of these 
diseases is underlying inflammation [14] and treating the inflammation through 
dietary change may result in the treatment of multiple disease states.
Although OA affects a large number of Americans, there are no proven therapies 
for preventing or halting its progression. In the normal joint, there is a balance 
between synthesis and degradation of cartilage. In inflammatory conditions such as 
OA, and other chronic diseases, catabolic molecules are upregulated, thereby inter-
rupting the function of anabolic molecules [15]. Catabolic cytokines also induce the 
production of specific matrix degrading metalloproteases, causing cartilage degra-
dation [16]. This finding has been confirmed by the increased level of these cyto-
kines in people with OA [17]. Unregulated or excess production of these molecules 
may play a detrimental role in the pathophysiology of OA [16, 18].
The development of OA is also accompanied by increased production of prostaglan-
dins (PGs), molecules that may contribute to joint damage, pain, and inflammation 
[19]. Cyclooxygenase (COX) is responsible for the production of PGs and exists as two 
distinct isoforms, COX-1, and COX-2. Increased expression of COX-2 has been demon-
strated in synovial tissues suggesting that COX-2 expression mediates the inflammatory 
response in OA [20]. COX-2 is undetectable in most tissues, but is increased in inflam-
mation leading to overproduction of PGE2 [21, 22]. Inhibition of these enzymes by non-
steroidal anti-inflammatory drugs (NSAID) and selective COX-2 inhibitors reduces the 
levels of PGs, resulting in a reduction in pain and inflammation.
Finding nutritional interventions to target the COX-2 pathway while allowing 
other necessary inflammatory pathways to function would significantly increase 
quality of life as well as functionality of individuals with OA. It may also inadver-
tently target unregulated inflammation that has been associated with other chronic 
disease states, and allow for affected individuals to exercise thus further decreasing 
their risk for the aforementioned chronic diseases.
Soy appears to be a promising treatment for those with OA, and has many other 
health benefits. Soy protein is low in saturated fat, contains all of the essential amino 
acids, and is also a good source of fiber, iron, calcium, zinc, and B vitamins [23]. This 
book chapter will focus on soy and its relationship to OA and other chronic diseases.
2. Nutrition profile of soy
Soy is a very nutritious plant, and the only complete plant protein. Protein in 
soy is not only high, but comparable in quality to animal protein regarding amino 
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acid content and digestibility [24]. The carbohydrate content of soybeans is not only 
low, but poorly digested by intestinal enzymes, and thus behaves as a prebiotic for 
beneficial bacteria [25]. The fat content is highly variable among different soybean 
varieties, but includes 10–15% saturated fat, 19–41% monounsaturated fat, and 
46–62% polyunsaturated fat [26].
Most notably, soybeans contain isoflavones. The three main isoflavones present 
in soybeans include genistein (50% of isoflavones), daidzein (40% isoflavones) and 
glycitein (10% of isoflavones) [27]. Isoflavones are also classified as phytoestrogens 
because of their similar structure to estrogen (Illustrations 1 and 2). Isoflavones are 
more bioactive in their unconjugated (aglycon) form than their conjugated form, 
which must be hydrolyzed in the intestine to release the aglycons [28]. Additionally, 
fermented soy has more unconjugated isoflavones, thus making fermented soy 
foods more pharmacokinetically beneficial [29]. Soy isoflavones are also metabo-
lized by gut bacteria, which leads to many different metabolites, the most biologi-
cally active being euqol [30]. Equol is structurally similar to estrogen, but inhibits 
growth of mammary tumors and may act as a selective estrogen receptor modulator 
(SERM) [31]. Isoflavones have anti-oxidative and anti-inflammatory properties, as 
well as the ability to alter gene expression, specifically in estrogen-responsive genes 
[32]. It is this ability that often leads health practitioners to believe that soy may be 
dangerous for certain populations, specifically breast cancer, which will be later 
discussed in this chapter. However, these SERM like capabilities are responsible for 
many of soy’s positive effects on health.
Illustration 1. 
Similarity of isoflavones to estrogens.
Illustration 2. 
Structure of estrogen and isoflavones.
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3. Soy, estrogen, and breast cancer
Breast cancer is one of the most common cancers diagnosed in women in the 
United States, and is the second leading cause of death after lung cancer in women 
[33]. Breast cancer is strongly linked to ovarian hormones and estrogen levels 
[34]. Factors like high endogenous estrogen levels and hormone therapy have been 
implicated in increasing breast cancer risk [35]. Indeed, 2/3 of breast cancer cases 
are estrogen receptor (ER) positive [36].
Because soy isoflavones closely resemble estrogen, many health practitioners 
warn against soy consumption in women, women with breast cancer, and post-
menopausal women for fear that soy will behave like an estrogen molecule. In our 
opinion, this idea is misconceived, as soy isoflavones would likely compete with 
endogenous estrogen for binding receptor sites in the breast, thereby reducing 
estrogen-stimulated growth and proliferation in the breast tissue, and may reduce 
endogenous estrogen concentrations [37]. Indeed, it has been shown that soy 
isoflavones may act as an estrogen antagonist in estrogen rich environments, and an 
estrogen agonist in low estrogen environments [38]; there is also evidence that the 
bioavailability of soy isoflavones may be inversely related to estrogen levels [39].
Epidemiological studies have shown that soy isoflavones do exert a protective 
effect on breast cancer risk, indicating a 16% risk reduction per 10 mg of daily 
isoflavone consumed [40]. A Dutch study [41] found that high levels of plasma 
genistein were associated with up to a 32% decreased risk of breast cancer. A 2009 
study [42] that investigated soy food intake and breast cancer survival found that 
soy food consumption was associated with a marked decreased risk of both mortal-
ity and recurrence of breast cancer.
A 1997 study [43] found that genistein is a potent estrogen agonist and exhibited 
cell growth-inhibitory actions in breast cancer cells in vitro. A more recent study 
[44] also found that genistein works to inhibit topoisomerase II activity, thus 
resulting in the inhibition of breast cancer growth. Davis et al. [45] investigated 
the radioprotective effects of genistein by injecting female mice with the isoflavone 
24 h prior to receiving a toxic dose of radiation, and found that genistein treated 
mice expressed fewer DNA damage responsive and cell cycle checkpoint genes than 
untreated mice. Magee et al. [46] investigated the effect of coumestrol, glycitein, 
daidzein, and the metabolites equol and O-desmethylangolensin on MDA-MB-231 
cells, finding that each inhibited invasion by approximately 30% at the lowest dose, 
while genistein and coumestrol exerted the most potent inhibitory effects on inva-
sion at the highest dose.
A clinical trial by Shike et al. [47] supplementing soy isoflavones in women 
with breast cancer found that soy consumption did alter gene expression in breast 
cancer tumors, specifically in FANCC and UGT2A1 which have both been impli-
cated in the development of breast cancer tumors. There was a subset of tumors 
with upregulated FGFR2 expression, which is a marker of poor prognosis in breast 
cancer patients, and overall soy intake did not significantly change cell proliferation 
and apoptosis indices compared with the placebo group. While this initially sounds 
discouraging, the article points out that the clinical ramifications of this minor 
upregulation have yet to be determined.
Another common concern about soy supplementation in post-menopausal 
women, specifically, is that it causes lymphocytopenia, which is the condition 
of having low levels of lymphocytes in the blood. Some of these concerns stem 
from a multicenter study [48] published in 2001 where postmenopausal women 
supplemented 600 mg of ipriflavone, a synthetic isoflavone, for 3 years. Out of 234 
women, 13.2% developed subclinical lymphocytopenia (<0.5 × 103/mm3). Another 
2 year study [49] found that 3% of their participants also developed abnormal 
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lymphocyte numbers. Another study by Ben-Hurt et al. [50] found that post-
menopausal women also had higher monocyte levels, indicating that menopause 
definitively alters hematological parameters.
A rat study [51] by our lab refutes these results. Our study not only found that 
ovariectomy increased lymphocyte, monocyte, eosinophil, and basophil differen-
tial counts, but that soy isoflavones retuned leukocyte counts to pre-surgery levels. 
To test the truth of this in human populations, our lab also investigated the extent 
to which 1 year of 25 g soy protein containing 60 mg isoflavones supplementation 
alters lymphocyte counts in postmenopausal women [52]. This study indicated no 
effect on total and differential white blood cell counts in postmenopausal women, 
which may be due to the fact that the estimated isoflavone content of the soy protein 
was lower than the pharmacological dose at 60 mg.
Because leukocyte counts tend to go up with menopause, it is not necessarily 
a bad side effect for pharmaceutical doses of soy to bring down white blood cell 
counts. Additionally, the supplementation of soy protein did not have a significant 
impact on leukocyte levels, indicating that soy supplementation is generally safe for 
healthy postmenopausal populations.
4. Soy, estrogen, and OA
Interestingly, OA is often seen in postmenopausal women, and is three times 
more likely to be a problem for postmenopausal women rather than men [53]. 
Cartilage is an estrogen sensitive tissue, which may, in part, explain the gender dis-
parity. Because postmenopausal women experience a severe drop in the production 
of estrogen, it stands to reason that estrogen may be protective against the develop-
ment of OA. Some studies [54–56] have found an association between hysterectomy 
and OA, while others [57, 58] have found no association. A study by Gao et al. [59] 
found that estradiol (E2) deficiency as well as changes in estrogen metabolites are 
involved in the pathogenesis of OA. Increased cartilage and bone turnover has been 
found in multiple animal models of menopause [60], but contrary to a general 
belief that lack of estrogen in women is the cause of OA, Tsai and colleagues [61] 
have suggested that excessive level of synovial fluid estrogen is responsible for the 
development of OA in both men and women. Indeed, some studies have found that 
the direct administration of estrogen to the knee joint has increased OA instance 
and progression [62, 63]. Intraarticular estradiol injection to ovariectomized rabbits 
both upregulated ER and ultimately caused further cartilage degeneration [64].
Soy isoflavones are often referred to as phytoestrogens, and may be helpful in 
relieving some symptoms of OA, and possibly prevent its progression. The conforma-
tional binding of soy isoflavones is similar to that of a SERM, which have been shown 
to be effective estrogen agonists or antagonists [65]. Genistein is the most potent of 
the isoflavones, and can therefore hypothetically produce positive effects on cartilage 
by blocking the action of estrogen. In addition to the possibility of modulating ERs, 
soy isoflavones may be able to increase IGF-1 production and decrease inflammation 
while also acting as an antioxidant. IGF-1 is thought to slow cartilage degradation 
[66]. Because soy isoflavones may serve as a natural modulator of IGF-1 production, it 
is probable that consumption of soy would benefit people suffering from OA.
5. Soy, leptin, and OA
Leptin is of particular interest in the pathology of OA, as the severity of OA is 
associated with both weight and BMI [67, 68], and leptin is generally elevated in 
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obese individuals [69]. Leptin is a hormone secreted by adipocytes and is involved 
with energy homeostasis, namely through its ability to cross the blood brain barrier 
to decrease orexigenic neuropeptides and increase anorexigenic neuropeptides [70]. 
In healthy individuals, leptin is secreted in proportion adipose tissue and energy 
intake [71]. Leptin is generally thought of as a satiety hormone, although many 
obese individuals have “leptin resistance” [72] where the secretion of leptin in these 
individuals does not suppress appetite or lead to reduced energy intake.
The role of leptin may extend beyond energy homeostasis. BMI and plasma 
leptin levels in OA patients correlate positively [70]. Plasma leptin concentrations 
have also been found to be 3 times higher in premenopausal women than men [73]. 
Bao et al. [74] found that injecting the knee with leptin caused significant degrada-
tion of the cartilage. Additionally, leptin taken from the synovial joint has been 
found to be higher than plasma leptin concentrations [75].
Results from our research group, corroborates previous findings [76]. In this 
study, we examined the relationship between serum and synovial fluid concentra-
tions of leptin in both males and females with varying degrees of OA. Serum and 
synovial fluid samples were obtained from 20 men (mean age = 68.4 ± 10.8 years) 
and 20 women (mean age = 61.6 ± 12.4 years) with varying degrees of OA who 
underwent arthroscopic or total knee replacement surgery. We found that leptin 
concentrations in both the serum and synovial fluid of patients with knee OA 
increased according to disease severity. That is, as the level of OA became more 
severe, the leptin concentration also increased, in both men (Figure 1A) and 
women (Figure 1B). We also found a significant correlation between serum and 
synovial fluid leptin concentration and BMI in both men (Figure 2A and B)  
and women (Figure 3A and B) with OA. These findings indicate that leptin may in 
part play a role in the increased risk of OA related to obesity.
The mechanism by which leptin may contribute to the pathophysiology of OA is 
likely due to its place in the cytokine family [72]. Leptin may trigger immune responses 
by increasing the expression of adhesion molecules, likely through a pro-inflammatory 
cytokine pathway [77]. Additionally, mice without a working leptin gene (ob/ob) dem-
onstrated decreased secretion of inflammatory cytokines, while the administration of 
leptin to these mice restored inflammatory secretions [78]. Additionally, leptin receptors 
are present in the cartilage suggesting a direct action on this tissue. There is evidence [79] 
that leptin stimulates inflammatory markers Interlukin-6 (IL-6), Interlukin-8 (IL-8), 
nitric oxide, Interlukin-1 β (IL-1β), Tumor Necrosis Factor-alpha (TNFα), COX2, and 
PGE 2 in the joint thereby contributing to cartilage matrix breakdown.
Because of isoflavones’ role in inflammation, the negative action of excess leptin 
levels on cartilage may be suppressed by isoflavones. For example, rats fed a high fat 
Figure 1. 
The relationship between serum and synovial fluid concentrations of leptin and severity of OA in both men 
(A) and women (B).
7Evidence for the Effectiveness of Soy in Aging and Improving Quality of Life
DOI: http://dx.doi.org/10.5772/intechopen.85664
soy diet, or regular soy diet, were found to have lower serum leptin concentrations 
than those fed a high fat casein, or regular fat casein diet [80]. Their study [80] also 
found that the expression of inflammatory genes decreased along with the expres-
sion of leptin. Niwa et al. [81] also found that soy isoflavones decreased leptin 
secretion in the adipocytes of mice, and a study by Llaneza et al. [82] found that 
the consumption of 200 mg of soy isoflavone extract in postmenopausal women 
resulted in decreased leptin levels, as well as TNFα. Another study in overweight 
and obese subjects found that after 12 weeks of black soy peptide supplementation, 
serum leptin concentrations were significantly reduced from baseline [83].
These studies and our observations so far suggest that soy and its isoflavones are 
likely very efficacious in alleviating pain associated with OA and its symptoms, in 
part due to its ability to decrease inflammatory responses. Soy’s ability to mediate 
leptin and inflammatory immune responses may also be integral in both preventing 
OA, halting its progression, and improving the QOL of individuals affected.
6. Soy and OA
The main soy isoflavones include genistein, daidzein, and glycetine [84]. 
Genistein is structurally similar to ipriflavone [84], a synthetic isoflavone. SERMs 
such as tamoxifen [85] and ipriflavone [86] have both been shown to influence 
cartilage metabolism and reduce or alleviate the symptoms associated with 
OA. Therefore, it is conceivable to also expect that genistein similarly influences 
cartilage metabolism.
Our in vitro study [87] found that genistein had the capacity to reduce inflam-
mation in human chondrocytes. Indeed, in chondrocytes treated with LPS to induce 
inflammation, genistein significantly decreased COX-2 production (Figure 4), but 
Figure 2. 
The correlation between serum (A) and synovial fluid (B) leptin concentration and BMI in men with OA.
Figure 3. 
The correlation between serum (A) and synovial fluid (B) leptin concentration and BMI in women with OA.
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Figure 5. 
COX-1 levels in cytosolic fraction of chondrocytes. LPS, lipopolysaccharides; and GEN, genistein. Bars represent 
mean ± SE, n = 3 per treatment group.
did not have an effect on COX-1 production (Figure 5) [87]. This is of particular 
interest, as NSAIDs are thought to inhibit inflammation via COX-1 and COX-2 
dependent pathways, but are thought to cause damage because of the inhibition 
of COX-1, an important enzyme that regulates normal cellular processes and is 
expressed in most tissues [88]. This inhibited synthesis caused by most NSAIDS can 
negatively affect the maintenance and integrity of the gastric and duodenal mucosa, 
as well as lead to kidney issues [89, 90]. COX-2, however, is generally unexpressed 
by most tissues and is upregulated specifically by inflammation [91]. The seemingly 
selective inhibition of COX-2 by genistein provides a promising alternative to those 
who experience gastric distress due to the use of NSAIDs.
IL-1β, an inflammatory cytokine, was also measured in this study and was found 
to be lower in both the high and low doses of genistein (Figure 6) [87]. More impor-
tantly, YKL-40, a marker of human cartilage glycoprotein degradation [92], was 
found to be suppressed in genistein treated groups (Figure 7); however, the differ-
ence between the LPS and genistein groups did not reach statistical significance [87].
An animal study by Borzan et al. [93] also supports our clinical findings on soy. 
The aim of the aforementioned study was to determine if a soy diet could reduce 
the pain behaviors and inflammation induced by the intraplantar administration of 
complete Freund’s adjuvant. They reported that neuropathic pain following partial 
sciatic nerve injury was attenuated in rats fed a soy protein diet [93], indicating that 
soy may be effective in attenuating pain symptoms, including those of OA.
Figure 4. 
COX-2 levels in cytosolic fraction of chondrocytes. LPS, lipopolysaccharides; and GEN, genistein. Bars represent 
mean ± SE, n = 3 per treatment group. Bars with different letters are significantly different from each other 
(P < 0.05).
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Lymphocytes and monocytes are often seen at sites of injury and inflammation 
[51]. Our lab investigated the effect of soy isoflavone supplementation on ovariec-
tomy induced lymphopoiesis in rats. In this animal study [94], we observed that 
ovariectomy-induced increases in peripheral blood total lymphocyte and monocyte 
counts were returned to the levels of sham-operated rats after soy isoflavone supple-
mentation (Figure 8A and B). Forty-eight 12-month-old Sprague-Dawley rats were 
either sham-operated (sham; 1 group) or OVX (3 groups) and were fed a standard 
semi-purified diet for 120 days. Thereafter, the OVX groups received one of the 
three doses of isoflavones: 0 (OVX), 500 (ISO500), or 1000 (ISO1000) mg/kg diet 
for 100 days. Ovariectomy significantly (P < 0.05) increased the total leukocyte, 
lymphocyte, monocyte, eosinophil, and basophil counts. Isoflavones at 500 and 
1000 mg/kg diet returned the total leukocyte counts as well as leukocyte subpopula-
tions to levels comparable to that of sham. These findings indicate that isoflavones 
are capable of normalizing circulating levels of inflammatory cells that produce 
many proinflammatory mediators, which may prove effective for the synovial joint.
Our lab also carried out a three-month double-blind randomized clinical trial 
[95] to investigate the effects of soy supplementation on symptoms associated with 
knee OA. About 135 free-living individuals (64 men, mean age = 55.8 ± 13.6 years; 
and 71 women, mean age = 59.3 ± 12.0 years) with knee OA were randomly assigned 
to receive 40 g of either soy protein or milk protein daily. This study indicated that 
soy protein regimen containing 88 mg isoflavones improved (P < 0.05) knee range 
of motion and ability to climb several flights of stairs, and reduced (P < 0.05) the 
intensity, frequency, severity of pain, hindrance to activities (Figure 9A), and use of 
pain medications (Figure 9B). The improvement in self-described pain parameters 
Figure 6. 
IL-1β level in culture supernatant measured via ELISA kit. LPS, lipopolysaccharides; and GEN, genistein. Bars 
represent mean ± SE, n = 4 per treatment group.
Figure 7. 
YKL-40 level in culture supernatant which was measured via ELISA kit. LPS, lipopolysaccharides; and GEN, 
genistein. Bars represent mean ± SE, n = 4 per treatment group.
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Figure 9. 
(A) represents self-reported pain limiting physical activities with scores ranging from 1 to 2; (1) referring to 
no limitation and (2) referring to pain as causing limitation in physical activity. (B) indicates the use of pain 
medications (mean + SE). A lower score reflects less use of pain medication and a higher score reflects more 
frequent use of pain medication.
due to soy supplementation became more pronounced as the treatment duration 
progressed. Additionally, the soy regimen significantly improved circulating levels of 
IGF-I which suggests that isoflavones may exert anabolic effects on the cartilage.
In the same study, serum IGF-I as well as human cartilage glycoprotein 39 (YKL-
40), a marker of joint destruction [92], were assessed. Results indicated that protein 
supplementation had significantly lowered mean serum concentration of YKL-
40 in men, implying that soy can slow down cartilage degradation. Although both 
proteins, as expected, increased (P < 0.05) circulating levels of IGF-I, soy protein 
had a more pronounced effect compared to milk protein. We have repeatedly shown 
[84, 96] that soy has the ability to uniquely enhance serum IGF-I in comparison 
with milk protein, indicating that this effect may be due to its isoflavone content 
rather than merely protein.
The findings of our three-month study indicate that soy protein supplementa-
tion significantly reduced the intensity and frequency of pain. By comparison, 
milk protein only reduced pain intensity indicating that the reduction in the 
frequency of pain and discomfort are specific to soy and not the control protein. 
Our findings also indicate a reduced need for pain medication. The increased serum 
IGF-I level with soy supplementation suggests that isoflavones may exert anabolic 
effects on the cartilage, and decreased YKL-40 levels which is associated with 
cartilage degeneration, support our hypothesis that soy can improve symptoms and 
severity of OA. The authors suggest that people with no contraindications to soy 
isoflavones use ipriflavone, a synthetic isoflavone, for decreasing the symptoms of 
OA. However, this is just a suggestion and further research must be done to assess 
the potency of isoflavone usage for symptomatic control of OA.
Figure 8. 
(A and B) Indicate effects of isoflavones (ISO) on lymphocyte and monocyte counts. Values are mean ± SE 
(n = 12). Bars that do not share the same superscript are significantly different (P < 0.05).
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7. Soy and cardiovascular disease
As mentioned previously, soy isoflavones are phytoestrogens. Estrogen is known 
to be cardioprotective, so it stands to reason that soy may also be cardioprotec-
tive. Many of the clinical trials investigating the effect of soy supplementation on 
heart health focus mainly on cholesterol levels. This may be due to the fact that the 
phytosterols, like those found in soy, compete with cholesterol for intestinal absorp-
tion [97]. A 2015 study [98] investigated the effect of 8 weeks of standard soymilk 
supplementation against the effect of 2 g/day of phytosterols and 10 g/day of 
inulin-enriched soymilk supplementation. While both groups did see a reduction in 
LDL-C in both groups, the study group supplementing with the extra phytosterols 
and inulin saw significantly better results. TC was also significantly reduced in the 
study group, compared to the control of regular soymilk.
Soy can be beneficial in many forms beyond that of soymilk. A study [99] that 
supplemented whole soy foods (3–4 servings per day) for 12 weeks found that the 
soy intervention significantly reduced total cholesterol, LDL-C, non-HDL cho-
lesterol, and apoB even though BMI did not decrease. An earlier study [100] also 
found that soy protein supplementation resulted in decreased cholesterol levels. 
Prehypertensive women who supplemented 40 g of soy flour saw decreases in 
LDL-C and well as high sensitivity C-Reactive Protein (CRP), a marker of inflam-
mation [101]. Interestingly, another study found that 1 month of soy nut supple-
mentation modestly reduced arterial stiffness but did not improve inflammatory 
biomarkers [102]. Additionally, Lucas et al. [103] found that soy isoflavones pre-
vented both hyperlipidemia and atherosclerotic lesions in ovariectomized Golden 
Syrian Hamsters.
While there are still gaps in the research for CVD and soy consumption, research 
generally points to a positive effect of soy on heart health, irrespective to its effect 
on cholesterol. Finding that soy significantly decreased the development of athero-
sclerotic lesion in a hamster model of postmenopausal CVD is particularly impor-
tant since CVD remains the leading cause of death in the US.
8. Soy and osteoporosis
Just as OA greatly affects women more so than men, osteoporosis is a particu-
larly concerning problem for the aging female population. Because intestinal cells 
contain ER, and because estrogen enhances calcium transport [104], it stands to 
reason that phytoestrogens like soy may increase intestinal calcium transport. There 
have been multiple studies researching intestinal transport of calcium and soy, as 
well as the effect of soy on animal models of osteoporosis, and human studies. A 
study by our lab in 2001 [104] confirmed that not only does ovariectomy decrease 
rates of calcium transport, but that soy isoflavones in soy protein promoted calcium 
absorption in a manner analogous to estrogen without any of the side effects/risk. 
Pawlowski et al. [105] also found that soy isoflavones were effective in increas-
ing calcium retention in bone, and Arjmandi et al. [84] found that women not on 
hormone replacement therapy who supplemented soy protein experienced reduced 
urinary calcium excretion.
Animal studies have yielded positive results for isoflavone’s bone sparing 
properties. A 1998 study [106] by our lab compared casein protein and soy protein 
in ovariectomized (OVX) rats, and found that soy protein with higher levels of 
isoflavones spared the femoral bone density decreases brought about by ovariec-
tomy. Our 2006 study [107] found that soy positively affected tibial architectural 
properties of OVX rats, including trabecular thickness, separation, and number 
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without preserving BMD. Another study by our lab [108] found that soy protein 
with or without isoflavones did not preserve BMD in a male rat model of osteopo-
rosis, but did positively affect the biomechanical properties of bone including yield 
and ultimate force which are measures of elasticity and plasticity in bone. Multiple 
other studies have concluded that any bone sparing effects of soy consumption are 
likely due to soy isoflavone content, which increases bone formation and improves 
the architectural properties of bone [109–112].
Interestingly, while animal studies have been promising for moderate prevention 
of bone loss, a 2-year Thai study [113] found that soy isoflavones did not signifi-
cantly reduce bone loss. Similarly, a 3-year study [114] that gave postmenopausal 
women soy isoflavones did not find significant bone sparing effects, except for 
the femoral neck which was still only modestly affected by supplementation. The 
same lab then evaluated the safety of soy isoflavone supplementation by evaluating 
effects on hormones, endometrial thickness, and any adverse events, finding no 
negative evidence of treatment effect on this population, once again indicating that 
soy supplementation is safe. Wong et al. [115] found that 120 mg of soy isoflavones 
did reduce whole body BMD loss, but did not positively affect common female 
fracture sites. Studies by our lab [96, 116], and others [117], generally find that soy 
supplementation for the treatment of osteoporosis generally has little to no effect on 
BMD, but may still positively affect bone metabolism as well as bone quality.
9. Conclusions and future directions
Although the role of soy in CVD, lowering cholesterol, and improving bone has 
been questioned, there is ample evidence to suggest that soy improves symptoms of 
OA by at least three mechanisms, including (1) acting as a SERM, thereby modulat-
ing estrogen receptors; (2) increasing circulating levels of IGF-1, thereby regenerat-
ing cartilage and/or preventing further damage; (3) and inhibiting production of 
inflammatory molecules, such as COX-2, TNF-α. The authors believe that soy plays 
an important role in the healthy aging process by decreasing the incidence of OA, 
and allowing those who are afflicted to achieve greater mobility, thus decreasing 
their chances of developing other chronic diseases that would have resulted from 
decreased mobility. Therefore, we suggest that consumption of soy and soy isofla-
vones is crucial for healthy aging and improved QOL throughout the aging process.
We have demonstrated that both leptin and estrogen have a significant role in 
the etiology, progression, and treatment of OA, but the specifics of that role remain 
uncertain. The above studies also indicate a positive effect of soy supplementation 
on cartilage metabolism, inflammation, and indices of pain, likely through the 
modulation of the aforementioned factors. Soy appears to be promising in the treat-
ment of OA symptoms, but its ability to prevent the disease is questionable. While 
isoflavones are known to act as SERMs, it is reasonable to suspect that the protein 
content of soy as a whole in conjunction with isoflavone content is responsible for 
positive effects in this population. Though the literature indicates that soy supple-
mentation may be helpful in decreasing usage of NSAIDs, slow cartilage degrada-
tion, and increase functionality in individuals afflicted with OA, determining the 
safety as well as the efficacy of soy or its isoflavones as a long-term OA intervention 
is the next logical step. Any intervention that can improve the QOL of individuals 
afflicted with OA is worth pursuing, but it is paramount that researchers uncover 
the exact etiology of the disease so as to prevent future occurrences.
The literature referenced here also indicates that soy can be promising for other 
chronic disease states, without necessarily posing a risk for increased instance of 
breast cancer. However, there is still much confusion about which populations are 
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at higher risk for breast cancer when consuming soy. The multiple health benefits 
appear to outweigh breast cancer risk for most women, even decreasing the chance 
of breast cancer, but further interventional, rather than strictly epidemiological 
and cell culture studies, need to be established.
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